Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?
作者信息
Kim Yeonhee, Song Woo-Jung
机构信息
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
出版信息
Allergy Asthma Immunol Res. 2025 Jul;17(4):405-408. doi: 10.4168/aair.2025.17.4.405.
Abstract
摘要
相似文献
1
Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?超越临床缓解：重新定义重度哮喘的疾病控制？
Allergy Asthma Immunol Res. 2025 Jul;17(4):405-408. doi: 10.4168/aair.2025.17.4.405.
2
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register.使用度普利尤单抗治疗重度哮喘患者的临床反应与缓解情况：来自丹麦全国重度哮喘登记处的结果
Respir Med. 2025 Aug-Sep;245:108203. doi: 10.1016/j.rmed.2025.108203. Epub 2025 Jun 11.
3
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.接受生物疗法治疗的重度哮喘患者的临床反应与缓解情况。
Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
4
Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making.重度哮喘患者生物治疗的停药情况：一项关于影响临床缓解及医生决策因素的真实病例研究
Allergy Asthma Proc. 2025 Jul 1;46(4):287-295. doi: 10.2500/aap.2025.46.250023.
5
XALOC-1: Clinical Remission Over 2 Years With Benralizumab in Severe Eosinophilic Asthma.XALOC-1：使用贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘两年实现临床缓解
Chest. 2025 Jul;168(1):19-32. doi: 10.1016/j.chest.2025.04.011. Epub 2025 Apr 19.
6
Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania.生物疗法是实现重度哮喘缓解的有效工具吗？罗马尼亚中部的一项回顾性研究。
Life (Basel). 2025 Jul 16;15(7):1113. doi: 10.3390/life15071113.
7
Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘时临床缓解对生活质量的影响。
Ann Allergy Asthma Immunol. 2025 Jun 20. doi: 10.1016/j.anai.2025.06.017.
8
Clinical Remission by a Comprehensive Severe Asthma Management Strategy Guided by Airway Inflammometry and Bioimaging.由气道炎症测定法和生物成像引导的综合重症哮喘管理策略实现临床缓解
Am J Respir Crit Care Med. 2025 Sep;211(9):1622-1635. doi: 10.1164/rccm.202412-2438OC.
9
Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.特泽佩umab实现临床和生物学缓解：重度难治性哮喘的真实世界反应
Allergy. 2025 Jun;80(6):1669-1676. doi: 10.1111/all.16590. Epub 2025 May 14.
10
Response to IL-5/IL-5R Antagonists and Remission Rate in Patients With Severe Asthma Who Would Have Been Excluded From the Pivotal Clinical Trials.对白细胞介素-5/白细胞介素-5受体拮抗剂的反应以及在严重哮喘患者中的缓解率，这些患者原本会被排除在关键临床试验之外。
J Allergy Clin Immunol Pract. 2025 Jul;13(7):1768-1775. doi: 10.1016/j.jaip.2025.03.025. Epub 2025 Mar 26.
本文引用的文献
1
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.接受美泊利珠单抗治疗的嗜酸性粒细胞型重度哮喘中国患者的临床缓解结果：一项3期随机双盲安慰剂对照试验的分析
Allergy Asthma Immunol Res. 2025 Jul;17(4):473-485. doi: 10.4168/aair.2025.17.4.473.
2
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR).美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的真实世界有效性和安全性：来自韩国重度哮喘登记研究（KoSAR）的见解
Allergy Asthma Immunol Res. 2025 May;17(3):384-393. doi: 10.4168/aair.2025.17.3.384.
3
Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment.时间就是肺：早期使用美泊利单抗治疗后，重度哮喘患者的肺功能得到更高程度的保留。
ERJ Open Res. 2025 Feb 3;11(1). doi: 10.1183/23120541.00211-2024. eCollection 2025 Jan.
4
Biologics in severe asthma: a state-of-the-art review.重度哮喘中的生物制剂：最新综述
Eur Respir Rev. 2025 Jan 8;34(175). doi: 10.1183/16000617.0088-2024. Print 2025 Jan.
5
On-treatment clinical remission of severe asthma with real-world longer-term biologic use.在现实世界中长期使用生物制剂治疗重度哮喘的治疗期临床缓解情况。
J Allergy Clin Immunol Glob. 2024 Oct 30;4(1):100365. doi: 10.1016/j.jacig.2024.100365. eCollection 2025 Feb.
6
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.以患者为中心的综合评分作为评估儿童和成人重度哮喘生物治疗反应的工具。
Eur Respir J. 2025 Mar 27;65(3). doi: 10.1183/13993003.00691-2024. Print 2025 Mar.
7
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.美泊利单抗治疗重度嗜酸性粒细胞性哮喘的长期临床疗效及持续缓解：REMI-M研究
J Allergy Clin Immunol Pract. 2024 Dec;12(12):3315-3327. doi: 10.1016/j.jaip.2024.08.033. Epub 2024 Aug 27.
8
Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR.生物制剂在重度哮喘患者中的真实世界有效性：KoSAR分析
Allergy Asthma Immunol Res. 2024 May;16(3):253-266. doi: 10.4168/aair.2024.16.3.253.
9
Remission in the World of Severe Asthma.重度哮喘领域的缓解
Am J Respir Crit Care Med. 2024 Oct 1;210(7):855-857. doi: 10.1164/rccm.202405-0894ED.
10
Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab.美泊利单抗治疗三年的最佳疗效重度哮喘患者临床缓解情况评估
Biomedicines. 2024 Apr 26;12(5):960. doi: 10.3390/biomedicines12050960.
Zotero 插件